Tadalafil Tablet, Film Coated
Product Images NDC 72789-408

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 72789-408). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pd-rx Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

72789408 Label (72789408)

This is a pharmaceutical product containing Tadalafil (10mg) in the form of 30 tablets per pack. The lot number is H21820 with an expiration date of November 2025. It is recommended to take one tablet daily. Each tablet contains 10mg of Tadalafil USP. The packaging includes reorder information and organoleptic markings for identification.*

FDA Label Image

Tadalafil-figure-1 (Tadalafil Figure 1)

FDA Label Image

Tadalafil-figure-2 (Tadalafil Figure 2)

This text appears to be a comparison chart showing the standing systolic blood pressure and supine systolic blood pressure readings over time post-dose, for a group taking Tadalafil 20 mg & doxazosin 8 mg versus a group taking Placebo & doxazosin 8 mg. The chart indicates measurements at various time points and suggests a comparison of the effects of the two treatments on blood pressure.*

FDA Label Image

Tadalafil-figure-3 (Tadalafil Figure 3)

The provided text appears to show a comparison of systolic blood pressure measurements at different times and under different medication conditions. The text includes information about the administration of 20 mg of tadalafil and 8 mg of doxazosin at different times and in combination with either placebo or doxazosin. The data seems to be analyzed based on the effect on systolic blood pressure over time for each of the mentioned conditions.*

FDA Label Image

Tadalafil-figure-4 (Tadalafil Figure 4)

This text provides information on the Plasma Tadalafil Concentration (µg/L) over time after the administration of different doses of Tadalafil. It includes data points for a single 20-mg dose, single 5-mg dose, and once-daily 5-mg dose following 5 consecutive days of administration. The timeline is measured in hours and shows the fluctuation of Tadalafil concentration in plasma.*

FDA Label Image

Tadalafil-figure-5 (Tadalafil Figure 5)

Change from Baseline in IPSS Total Score is being evaluated over 12 weeks for individuals taking Tadalafil Tablets 5 mg. The data is collected at 4, 8, and 12 weeks to assess the effectiveness of the treatment over time.*

FDA Label Image

Tadalafil-figure-6 (Tadalafil Figure 6)

This information provides data on the change from baseline in the IPSS Total Score, comparing the effects of Tadalafil Tablets 5 mg to a placebo over a 24-week treatment period. The study indicates a statistically significant difference between the two groups at a significance level of P<0.01.*

FDA Label Image

Tadalafil-figure-7 (Tadalafil Figure 7)

This text provides information on the LS mean change from baseline over different weeks of therapy for Tadalafil/Finasteride and Placebo/Finasteride. It includes the least-squares treatment difference between the two, highlighted with specific values and statistical significance markers.*

FDA Label Image

Tadalafil-figure-8 (Tadalafil Figure 8)

FDA Label Image

Tadalafil-structure (Tadalafil Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.